Target Information

Target General Infomation
Target ID
T10877
Former ID
TTDNC00424
Target Name
CD38
Gene Name
CD38
Synonyms
ADPribosyl cyclase 1; Cyclic ADPribose hydrolase 1; T10; cADPr hydrolase 1; CD38
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Hematological malignancies [ICD9: 200-209; ICD10: C81-C86]
Multiple myeloma [ICD9: 203; ICD10: C90]
Function
Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.
BioChemical Class
Glycosylases
UniProt ID
P28907
EC Number
EC 3.2.2.5
Sequence
MANCEFSPVSGDKPCCRLSRRAQLCLGVSILVLILVVVLAVVVPRWRQQWSGPGTTKRFP
ETVLARCVKYTEIHPEMRHVDCQSVWDAFKGAFISKHPCNITEEDYQPLMKLGTQTVPCN
KILLWSRIKDLAHQFTQVQRDMFTLEDTLLGYLADDLTWCGEFNTSKINYQSCPDWRKDC
SNNPVSVFWKTVSRRFAEAACDVVHVMLNGSRSKIFDKNSTFGSVEVHNLQPEKVQTLEA
WVIHGGREDSRDLCQDPTIKELESIISKRNIQFSCKNIYRPDKFLQCVKNPEDSSCTSEI
Drugs and Mode of Action
Drug(s) Daratumumab Drug Info Approved Multiple myeloma [524935], [542416]
MOR-202 Drug Info Phase 1/2 Multiple myeloma [523595]
SAR-650984 Drug Info Phase 1/2 Hematological malignancies [522969]
Modulator HuMax-CD38b Drug Info [543705]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Nicotinate and nicotinamide metabolism
Metabolic pathways
Calcium signaling pathway
Hematopoietic cell lineage
Oxytocin signaling pathway
Salivary secretion
Pancreatic secretion
Epstein-Barr virus infection
NetPath Pathway Leptin Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway CCKR signaling map ST
WikiPathways Oxytocin signaling
References
Ref 522969ClinicalTrials.gov (NCT01084252) Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies. U.S. National Institutes of Health.
Ref 523595ClinicalTrials.gov (NCT01421186) A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 524935ClinicalTrials.gov (NCT02252172) Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma. U.S. National Institutes of Health.
Ref 542416(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395).
Ref 533308Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
Ref 543705(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2766).
Ref 551961Clinical pipeline report, company report or official report of MorphoSys.
Ref 551980Clinical pipeline report, company report or official report of Sanofi-Aventis.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.